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Chlamydia pneumoniae is the most commonly occurring intracellular bacterial pathogen. It is frequently involved in 
respiratory tract infections and to a lesser degree in extrapulmonary diseases. According to seroepidemiologic surveys, 
C. pneumoniae infection seems to be both endemic and epidemic. Such studies indicate that C. pneumoniae infection 
is widespread, with frequent reinfection during a lifetime. In Western countries the highest rate of new infections occurs 
between the ages of 5 and 15. The antibody prevalence worldwide is higher in adult males than in females. Currently 
available data suggest that C. pneumoniae is primarily transmitted from human to human without any animal reservoir. 
Transmission seems to be inefficient, although household outbreaks with high transmission rates are reported. Most 
reports rank C. pneumoniae among the three most common etiologic agents of community-acquired pneumonia, with 
an incidence ranging from 6% to 25%, and generally presenting a mild and, in some cases, self-limiting clinical course. 
Recent reports also indicate a possible role for C. pneumoniae in severe forms of community-acquired pneumonia and 
in respiratory infections in immunocompromised patients. C. pneumoniae infection has also been implicated in the 
pathogenesis of asthma in both adults and children. The hypothesis that C. pneumoniae infection could lead to asthma 
is based on clinical studies and on the evidence of specific IgE production, direct epithelial damage, induction of T-cell 
immunopathologic diseases, and vascular smooth cell infection. Chronic C. pneumoniae infection seems to be common 
in patients with chronic bronchitis whether exacerbated or not, and is characterized by a strong humoral immune 
response to this intracellular microorganism, which is present in the majority of patients with severe chronic bronchitis. 
More than 60% of subjects with chronic bronchitis have specific C. pneumoniae antibody titers, and the microorganism 
may be identified by culture or PCR in almost 40% of these patients. This pathogen has also been recently associated 
with atherosclerosis and coronary heart disease (CHD). Seroepidemiological evidence indicates that the majority of 
patients with CHD present an anti-C. pneumoniae antibody pattern consistent with chronic infection. Furthermore, 
C. pneumoniae has been detected in atherosclerotic coronary plaques by several methods, including immunocyto- 
chemistry, transmission electron microscopy and molecular biology techniques. Recently, we detected C. pneumoniae 
DNA in a high percentage (51%) of aortic aneurysm plaques. Moreover, our serologic data support the hypothesis that 
a chronic C. pneumoniae antibody pattern may be a possible risk marker for atherosclerosis. Recently, C. pneumoniae 
has been isolated by culture from the coronary artery of a patient with coronary atherosclerosis, providing direct 
evidence of the presence of viable organisms in atheromatous lesions. Moreover, we recently demonstrated an 
association between C. pneumoniae reinfection and acute myocardial infarction. 
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In 1989, the previously labeled Chlamydia strain 
TWAR was recognized as a third species of the 
Chlamydia genus on the basis of ultrastructural and 
DNA homology analysis and named Chlamydia 
pneumoniae [l]. Like other Chlamydia species, this agent 
is an obligate intracellular, Gram-negative bacterium 
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present in two developmental forms: infective element- 
ary bodies (EBs) and reproductive reticulate bodies 
(RBs).  Chlamydia possesses a specific replication cycle 
which differs from that of conventional bacteria. 
It multiplies within membrane-bound vacuoles in 
eukaryotic host cells but is unable to generate ATP and 
is therefore dependent on the host-cell ATP deposits 
for all energy requirements. Moreover, it is incapable of 
de novo nucleotide biosynthesis and is dependent on 
host nucleotide pools [2]. 
C .  pneumoniae has been recognized as a cause of 
respiratory tract infections and is considered to 
be the most common non-viral intracellular human 
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respiratory pathogen [3,4]. C. pneumoniae is involved in 
a wide spectrum of infections of the upper respiratory 
tract (pharyngitis, sinusitis and otitis) and lower respir- 
atory tract (acute bronchitis, exacerbations of chronic 
bronchitis and asthma, and community-acquired 
pneumonia) in both immunocompetent and immuno- 
compromised hosts [5-221. This agent has also been 
associated with another pulmonary disease (sarcoidosis) 
123,241 and extrapulmonary diseases (coronary artery 
diseases, erythema nodosum, Guillain Barrk syndrome, 
culture-negative endocarditis, thyroiditis, arthritis, 
encephalitis) [2S-35]. 
TRANSMISSION 
Current available data suggest that C. pneumoniae is 
primarily transmitted by human to human contact and 
so far no animal reservoir has been found [9,36]. 
Outbreaks in closed communities such as military 
garrisons, schools and families have been repeatedly 
observed [9,13-17,371. 
C. pneumoniae can remain viable on environmental 
surfaces for long periods of time and is transferable to 
hands, although survival time on skin appears to be 
brief. This agent appears to survive well in aerosolized 
particles of <5 pm, and its survival appears to be 
favored by low ambient temperature and high relative 
humidity [38]. C. pneumoniae infection spreads slowly 
with a case-to-case interval of about 30 days. Serologic 
data show that the durations of epidemics vary from 5 
to 8 months, suggesting a relatively long incubation 
period. Such studies have shown a worldwide diffusion 
of C. pneumoniae infection. In developed countries the 
infection seems to be rather uncommon before the age 
of 5 .  Seroprevalence increases during the school years 
and reaches over 50% in middle-aged adults [18,39,40]. 
The antibody prevalence is higher in males than in 
females. 
Seroepideniiologic data from developing countries 
show a higher overall prevalence. In these populations 
pre-school infection seems to be rather frequent and 
seroprevalences reach more than 70% in adults [41]. 
Family transmission, child to child, has been described 
in Japan [14], and family outbreaks, with different rates 
of infection, have been reported [15-171. 
IMMUNITY 
The serologic response to C. pneurnoniae acute infection 
is characterized by two different patterns. By micro- 
immunofluorescence (MIF) assay, primary infection 
shows an IgM titer rise followed by an IgG increase, 
whereas reinfection shows IgG and IgA titer rises 
without an IgM increase. IgM antibodies are usually 
undetectable 2-3 months after acute infection, whereas 
IgG and IgA may persist for longer and could represent 
indirect evidence of persistent/chronic infection. Re- 
infections are common, and serum antibodies do not 
appear to be protective. 
Asymptomatic carriage of C. pneumoniue in 
subjectively healthy adults appears to be relatively 
uncommon, ranging from 2% to 4% of the general 
population [42,43]. In certain subjects, namely chronic 
obstructive pulmonary disease (COPD) patients, a 
higher percentage of chronic carriage/infection has 
been found [44,45]. 
ACUTE CHLAMYDIA PNEUMONIA€ RESPIRATORY 
INFECTIONS 
C. pneumoniae is an important cause of human respir- 
atory tract disease. This agent is involved in upper 
respiratory tract infections (pharyngitis, sinusitis), acute 
bronchitis and exacerbations of chronic bronchitis 
C. pneuinoniae is now known to be a relevant cause 
of community-acquired pneumonia, being involved in 
6% to more than 20% of cases [47]. Most recent reports 
rank it among the three most common etiologic agents, 
generally presenting a mild, and in some cases self- 
limiting, clinical course. This agent has been shown to 
cause severe forms of pneumonia, particularly in elderly 
patients, and in the presence of chronic cardio- 
pulmonary diseases [48,49]. A recent prospective study 
on community-acquired pneumonia in elderly patients 
[SO] also identified C. pneumoniae as the second most 
common pathogen, occurring in 9% of patients. As 
previously suggested [51], identification of C. pneu- 
tnoniae in mixed infections may indicate that this 
pathogen could facilitate infections by other micro- 
organisms. 
The potential ability of C. pnetimoniae to act as a 
respiratory pathogen in immunocompromised patients 
has recently been recognized. In 1991 this agent was 
isolated by culture in the lungs of HIV-infected subjects 
undergoing fiberbronchoscopy for unexplained 
pulmonary processes [19]. Gaydos et a1 [21] studied 132 
culture-negative bronchoalveolar lavage (BAL) speci- 
mens from 108 immunocompromised subjects with 
radiographically confirmed pulmonary involvement of 
the disease process. Twelve of these patients (11%) had 
PCR-enzyme imniunoassay (EIA)-positive specimens. 
Only two of the 12 infected patients had other 
microbiological agents implicated in pneumonia. The 
authors conclude that C. pneumoniae should be con- 
sidered in the evaluation and treatment of pneumonia 
in immunocompromised patients. 
[5-7,461. 
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A seroepidemiologic study suggested that HIV-1- 
infected subjects (both adults and children) seem to be 
at a higher risk of developing C. pneumoniae infection 
[18]. The same group later demonstrated an outbreak 
of C. pneumoniae infection in former injection-drug 
users. A higher infection rate was observed in HIV- 
positive than in HIV-negative subjects. Most infections 
presented clinically as pneumonia [22]. A further study 
on the same community of injection-drug users 
showed that, in 210 cases ofpneumonia, C. pneumoniae 
was the most common pathogen in HIV-negative 
subjects and the third most common pathogen in HIV- 
positive patients [52]. 
Recently, Dalhoff and Maass [53] reported a 
prospective clinical study on 47 HIV-positive patients, 
57 immunocompetent patients with pneumonia, and 
100 patients with non-infectious bronchopulmonary 
disorders. In all patients BAL and C. pneumoniae culture 
and DNA detection were performed. The pathogen 
was frequently detected in the BAL fluid of patients 
with pneumonia as a sole pathogen. C. pneumoniae was 
detected in nine of 57 immunocompetent and in six of 
47 immunocompromised patients, whereas no positive 
results were obtained in the 100 control patients. Co- 
infections with other organisms were frequent in HIV- 
positive patients (3/6), but did not occur in the 
immunocompetent group. Moreover, two of six HIV 
patients with chlamydial infection had no respiratory 
symptoms or radiographic abnormalities, and, in three, 
clinical presentation was consistent with the character- 
istics of other agents detected. The authors conclude 
that in the HIV-positive group, the association of 
C. pneumoniae detection and acute pulmonary infection 
is less clear than in immunocompetent patients, because 
asymptomatic carriage and copathogens were found. 
A possible role for C. pneumoniae in asthma has 
been recently hypothesized. In several patients the 
infection is associated with wheezing and asthma onset 
[I 1,541. Hahn reported a dose-response relationship 
between specific antibody titers and wheezing 
prevalence [l l] .  In that study, four patients with acute 
infection subsequently developed asthma and four 
others experienced an exacerbation of previously 
diagnosed asthma. Other groups demonstrated that 
C. pneumoniae causes asthma exacerbations. Allegra 
et al [12] found that about 10% ofasthma exacerbations 
in adults were due to this pathogen. Emre et al [54] 
reported similar results in a pediatric population. 
Moreover, they demonstrated that treatment with a 
inacrolide may improve the course of reactive airways 
disease. 
The results of these and other studies lead to the 
hypothesis that C. pneumoniae chronic infection may 
play a part in the natural history of asthma condition- 
ing, at least partly, in the chronic inflammation and 
hyperresponsiveness which characterize bronchial 
asthma. Only large epidemiological studies and ther- 
apeutic intervention, particularly double-blind studies 
against placebo, will clarifj the role of this pathogen in 
the etiopathogenesis of bronchial asthma. 
CARDIOVASCULAR DISEASES 
Known risk factors, e.g., smoking, hypercholesterol- 
emia, Lp(a) levels and hypertension, explain 50-70% 
of the etiopathogenesis of myocardial infarction. 
Recent evidence indicates the possible role of viral and 
bacterial infections in the development of athero- 
sclerosis and their association with myocardial 
infarction [25,55,56]. 
Seroepidemiologic evidence indicates that the 
majority of patients with coronary heart disease (CHD) 
present an anti-C. pneumoniae antibody pattern con- 
sistent with chronic infection [26-291. Furthermore, 
C. pneumoniae has been detected in atherosclerotic 
coronary plaques by several methods, including 
immunocytochemistry, transmission electron micro- 
scopy and molecular biology techniques [3&33]. We 
detected C. pneumoniae DNA in a high percentage of 
aortic aneurysm plaques [57]. Furthermore, our sero- 
logic data support the hypothesis that a chronic C. 
pneumoniae antibody pattern may be a possible risk 
marker for atherosclerosis. Recently, C. pneumoniae has 
been isolated by culture from the coronary artery of a 
patient with coronary atherosclerosis, providing direct 
evidence of the presence of viable organisms in athero- 
matous lesions [58]. 
We have found a high incidence of acute C. 
pneumoniae infection in patients with acute myocardial 
infarction [59]. Serology for C. pneumoniae was con- 
sistent with acute reinfection in 12 patients and with 
chronic infection in 23 patients, and was negative in 26 
patients with acute myocardial infarction. In three of 12 
cases with an acute reinfection pattern and in three of 
23 patients with a chronic infection pattern, C. 
pneumoniae DNA was detected on pharyngeal swab 
specimens. A significantly higher prevalence of IgG 
titers was observed in patients with acute myocardial 
infarction (35/61) than in blood donors (18/61) 
(p=0.003). These findings provide further evidence for 
the hypothesis that C. pneumoniae infection may act as 
a trigger for acute myocardial infarction. 
Recent reports have identified this agent in 
atherosclerotic coronary plaques and have detected 
immune complexes containing chlamydial lipopoly- 
saccharide in acute myocardial infarction [29,30]. C. 
pneumoniae reinfection could lead to instability within 
atherosclerotic plaques via a reactivation of a chronic or 
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latent infection and/or immune-mediated endothelial 
damage. The demonstration of an association between 
C. pneumoniae reinfection and acute myocardial infarc- 
tion is a new aspect that may be linked to the previously 
suggested role of chronic infection in the pathogenesis 
of atherosclerosis. The importance of chronic C. 
yneumoniae infection in C H D  is also confirmed by the 
high seroprevalence observed in our patients. The 
detection of C. pneumoniae on swab specimens in three 
of 23 patients with chronic serologic patterns is further 
evidence for the possible persistence of this pathogen 
in CHD patients. 
Juvonen et a1 1601 reported a high incidence of C. 
pnelrmoniae detection in non-rheumatic aortic valve 
stenosis, suggesting a possible role for the pathogen in 
the development of ‘degenerative’ aortic valve stenosis. 
C. pneumoniae was frequently found in advanced carotid 
atherosclerotic lesions, and although these findings do 
not establish a causal relationship between infection and 
atherosclerosis, they represent another link between C. 
prieimoniae and atherosclerosis development [61]. This 
study confirnis a previous report based on sero- 
epidemiologic evidence that showed a significant cross- 
sectional association between past C. pneninoniae infec- 
tion and asymptomatic carotid atherosclerosis [62]. 
Moreover, a recent study found an association between 
C. pneninoniae chronic infection, diagnosis based on 
serologic pattern, and increased risk of cerebrovascular 
disease, namely stroke and transient ischemic events [63]. 
Last, two prospective studies have shown that 
niacrolide treatment of patients with C H D  and C. 
przeumoniae-positive serology protects them from 
further cardiovascular events, compared to non-treated 
patients [64,65]. 
CONCLUSIONS 
The role of C. pneurnoniae infection in acute respiratory 
diseases, such as pneumonia and exacerbations of 
chronic bronchitis, has now been recognized. Data on 
this agent in HIV-positive subjects are insufficient to 
allow definitive conclusions, but suggest that Chlamydia 
act5 as a pathogen in these patients also. Moreover, there 
seeins to be an increased susceptibility of HIV patients 
to C. prieirmoniae, and experimental data suggest that 
Clzlaruydia may cause an increase of HIV replication, 
thus contributing to the evolution of opportunistic 
infections and disease progression [66]. 
A further issue of interest is the pathogenetic role 
of C. pncmmoniae in asthma and atherosclerosis. In 
patients with asthma, Chlamydia is certainly a cause of 
acute exacerbations, although its effect on the natural 
history of the disease deserves further study. Finally, a 
line of research of great future interest concerns the 
association between chronic C. pneumoniae infection 
and atherosclerosis. Should this be proven, the treat- 
ment of this infection may have a strong impact on 
public health. 
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